2024 World Conference on Lung Cancer (WCLC) - Posters-P1.06B.11 Plasma MicroRNAs Profiling to Monitor Immunotherapy Response in Advanced NSCLC Patients

Pdf Summary

The study conducted by Marta Brambilla focuses on utilizing plasma microRNA profiling to monitor the response of advanced non-small cell lung cancer (NSCLC) patients undergoing immunotherapy, particularly immune checkpoint inhibitors (ICIs). While ICIs have improved outcomes for NSCLC, many patients experience disease relapse due to resistance. This research aims to address the challenge of non-invasive biomarker identification for treatment monitoring and therapy personalization.<br /><br />The study is part of the APOLLO trial, which collected various clinical, biochemical, and molecular data, alongside plasma samples at specific intervals, from NSCLC patients receiving ICI monotherapy. The analysis was conducted on 454 plasma samples from 211 patients at Istituto Nazionale dei Tumori, Milan. Using a custom RT-qPCR platform, the researchers profiled 24 lung cancer-related circulating microRNAs, forming 276 microRNA ratios. They applied generalized estimating equations (GEE) to model disease progression, integrating these microRNA ratios over time.<br /><br />The results identified nine significant circulating microRNA ratios featuring miR-145, which served as predictors of disease progression, consistently aligning with radiological responses. Additionally, baseline levels of miR-140-5p/miR-145, among others, were related to overall survival (OS) but not progression-free survival (PFS).<br /><br />The conclusions suggest that dynamic microRNA profiles, especially involving miR-145, hold potential for assessing treatment responses in NSCLC patients undergoing ICI monotherapy. The study emphasizes that microRNA-based liquid biopsies represent a minimally invasive method for disease monitoring, which could enhance clinical decision-making and treatment efficacy by detecting disease progression earlier. Integrating such biomarkers into clinical practice could lead to significant improvements in managing advanced NSCLC.

Asset Subtitle

Marta Brambilla

Meta Tag

Speaker Marta Brambilla

Topic Pathology & Biomarkers

Keywords

plasma microRNA profiling

non-small cell lung cancer

NSCLC

immunotherapy

immune checkpoint inhibitors

ICIs

biomarker identification

microRNA ratios

miR-145

liquid biopsy